| 9-Apr-2026 |
Headline Regeneron expects ~$102M in Q1 pre-tax IPR&D charges (8-Apr-2026, 12:00 AM Seeking Alpha News) |
|
|
|
|
|
-1.0% |
|
|
|
|
|
|
|
|
|
|
| 3-Dec-2025 |
Headlines FDA top drugs official Pazdur retiring shortly after starting - report (2-Dec-2025, 12:00 AM Seeking Alpha News) Regeneron downgraded at Morgan Stanley on valuation level (3-Dec-2025, 12:00 AM Seeking Alpha News) |
|
|
|
|
|
-2.5% |
|
|
|
|
|
|
|
|
|
|
| 13-Oct-2025 |
Press Release DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss (12-Oct-2025, 10:18 AM Globe Newswire) HeadlineSA Asks: What's the most attractive biotech stock right now? (12-Oct-2025, 12:00 AM Seeking Alpha News) |
|
|
|
|
|
-1.2% |
|
|
|
|
|
|
|
|
|
|
| 23-Sep-2025 |
Press Releases Dupixent (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion (22-Sep-2025, 12:29 AM Globe Newswire) Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion (22-Sep-2025, 12:30 AM Globe Newswire) |
|
|
|
|
|
-4.7% |
|
|
|
|
|
|
|
|
|
|
| 30-May-2025 |
Press Releases Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies (30-May-2025, 1:00 AM Globe Newswire) Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials (30-May-2025, 1:00 AM Globe Newswire) HeadlinesIntellia slides after safety concern for Regeneron-partnered gene editing therapy (29-May-2025, 12:00 AM Seeking Alpha News) Sanofi, Regeneron fall after late-stage data for COPD therapy (30-May-2025, 12:00 AM Seeking Alpha News) Regeneron slumps as Wells Fargo cuts on COPD trial data (30-May-2025, 12:00 AM Seeking Alpha News) Kymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases asset (30-May-2025, 12:00 AM Seeking Alpha News) |
|
|
|
|
|
-19.0% |
|
|
|
|
|
|
|
|
|
|
| 23-May-2025 |
Market Gap DownSPY had a large negative gap on the day of -1.3% |
|
|
|
|
|
-1.4% |
|
|
|
|
|
|
|
|
|
|
| 8-May-2025 |
|
|
|
|
|
|
-2.4% |
|
|
|
|
|
|
|
|
|
|
| 1-May-2025 |
Press Releases Dupixent (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases (1-May-2025, 9:00 AM Globe Newswire) Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination (1-May-2025, 9:30 AM Globe Newswire) HeadlineRegeneron ordered to face lawsuit alleging Medicare fraud over Eylea (1-May-2025, 12:00 AM Seeking Alpha News) |
|
|
|
|
|
-1.5% |
|
|
|
|
|
|
|
|
|
|
| 9-Apr-2025 |
|
|
|
|
|
|
+3.6% |
|
|
|
|
|
|
|
|
|
|
| 13-Jan-2025 |
Press Releases Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman (10-Jan-2025, 8:38 AM Globe Newswire) DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders (10-Jan-2025, 12:09 PM Globe Newswire) REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (10-Jan-2025, 2:25 PM PRNewswire) Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action (10-Jan-2025, 2:49 PM Business Wire) INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel (10-Jan-2025, 5:55 PM Globe Newswire) REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (10-Jan-2025, 9:30 PM Business Wire) REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (12-Jan-2025, 4:00 PM PRNewswire) The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN (13-Jan-2025, 5:45 AM PRNewswire) REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (13-Jan-2025, 5:48 AM Business Wire) Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery (13-Jan-2025, 6:05 AM Globe Newswire) Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial (13-Jan-2025, 6:15 AM Globe Newswire) Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference (13-Jan-2025, 6:30 AM Globe Newswire) Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman (13-Jan-2025, 10:42 AM Globe Newswire) Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit (13-Jan-2025, 12:00 PM Business Wire) Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery Contact Levi & Korsinsky (13-Jan-2025, 12:13 PM Globe Newswire) ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit (13-Jan-2025, 3:44 PM PRNewswire) REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (13-Jan-2025, 4:00 PM Business Wire) REGN Shareholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors Class Action Against Regeneron Pharmaceuticals, Inc. (13-Jan-2025, 9:48 PM Globe Newswire) Headlines4D Molecular, FDA agree on phase 3 design for DME candidate (10-Jan-2025, 12:00 AM Seeking Alpha News) Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A? (11-Jan-2025, 12:00 AM Seeking Alpha News) Regeneron Pharmaceuticals met primary endpoint in cell carcinoma treatment trial (13-Jan-2025, 12:00 AM Seeking Alpha News) 4D Molecular downgraded at BMO on limited population for wet AMD candidate (13-Jan-2025, 12:00 AM Seeking Alpha News) Regeneron announces IPR&D charges (13-Jan-2025, 12:00 AM Seeking Alpha News) |
|
|
|
|
|
+2.9% |
|
|
|
|
|
|
|
|
|
|
| 10-Jan-2025 |
Press Releases REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) INVESTOR ALERT: Investors With Large Losses in Regeneron Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights (8-Jan-2025, 12:55 PM Globe Newswire) Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action (8-Jan-2025, 2:53 PM Business Wire) DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals (8-Jan-2025, 4:39 PM Business Wire) REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit (8-Jan-2025, 5:07 PM Globe Newswire) Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN) (8-Jan-2025, 6:11 PM Globe Newswire) Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit (8-Jan-2025, 6:38 PM Globe Newswire) REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm (8-Jan-2025, 7:30 PM Business Wire) Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman (8-Jan-2025, 9:29 PM Globe Newswire) Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman (9-Jan-2025, 2:25 PM PRNewswire) REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (9-Jan-2025, 4:00 PM Globe Newswire) Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report Hagens Berman (10-Jan-2025, 8:38 AM Globe Newswire) DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders (10-Jan-2025, 12:09 PM Globe Newswire) REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (10-Jan-2025, 2:25 PM PRNewswire) Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action (10-Jan-2025, 2:49 PM Business Wire) INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel (10-Jan-2025, 5:55 PM Globe Newswire) REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (10-Jan-2025, 9:30 PM Business Wire) HeadlinesNovo, Eli Lilly to dominate global pharma sales in 2025: report (9-Jan-2025, 12:00 AM Seeking Alpha News) 4D Molecular, FDA agree on phase 3 design for DME candidate (10-Jan-2025, 12:00 AM Seeking Alpha News) |
|
|
|
|
|
-5.0% |
|
|
|
|
|
|
|
|
|
|
| 8-Jan-2024 |
Press Releases Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 (5-Jan-2024, 4:05 PM Globe Newswire) Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo (cemiplimab) in Multiple Countries (8-Jan-2024, 7:30 AM PRNewswire) |
|
|
|
|
|
-1.1% |
|
|
|
|
|
|
|
|
|
|
| Simple Average Returns - 12 Largest Negative Opening Gaps |
| Avg Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Positive Occurrences |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Negative Occurrences |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Absolute Average Returns - 12 Largest Negative Opening Gaps |
| Abs Avg Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Max Abs Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Min Abs Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Median, Minimum, and Maximum Returns - 12 Largest Negative Opening Gaps |
| Median Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Max Positive Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Max Negative Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|